Diabetic ketosis during hyperglycemic crisis is associated with decreased all-cause mortality in patients with type 2 diabetes mellitus

Endocrine

Volumn 55, Issue 1, 2017, Pages 139-143

  Kruljac, Ivan ^a   Ćaćić, Miroslav ^a   Ćaćić, Petra ^b   Ostojić, Vedran ^c   Štefanović, Mario ^a   Šikić, Aljoša ^a   Vrkljan, Milan ^a  

^a SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

^c Croatian Academy of Medical Sciences   (Croatia)

Author keywords

Heart failure; Ketogenesis; Ketosis; Kidney disease; Mortality; Type 2 diabetes mellitus

Indexed keywords

GLUCOSE; GLYCOSYLATED HEMOGLOBIN;

AGED; ARTICLE; CAUSE OF DEATH; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETIC KETOACIDOSIS; FEMALE; HEART FAILURE; HUMAN; HYPERGLYCEMIA; INCIDENCE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; COMPLICATION; CROATIA; DIABETIC CARDIOMYOPATHIES; DIABETIC NEPHROPATHIES; HOSPITAL EMERGENCY SERVICE; KIDNEY DISEASES; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; REGISTER; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TEACHING HOSPITAL;

AGED; CROATIA; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC CARDIOMYOPATHIES; DIABETIC KETOACIDOSIS; DIABETIC NEPHROPATHIES; EMERGENCY SERVICE, HOSPITAL; HEART FAILURE; HOSPITALS, TEACHING; HUMANS; HYPERGLYCEMIA; INCIDENCE; KIDNEY DISEASES; MIDDLE AGED; MORTALITY; REGISTRIES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

EID: 84984911062     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-016-1082-7     Document Type: Article

References (21)

1. A. Avogaro, A. Valerio, L. Gnudi, A. Maran, M. Zolli, E. Duner, A. Riccio, S. Del Prato, A. Tiengo, R. Nosadini, Ketone body metabolism in NIDDM. Effect of sulfonylurea treatment. Diabetes 41, 968–974 (1992)
2. N. Geidenstam, P. Spégel, H. Mulder, K. Filipsson, M. Ridderstråle, A.P.H. Danielsson, Metabolite profile deviations in an oral glucose tolerance test-a comparison between lean and obese individuals. Obesity (Silver Spring) 22, 2388–2395 (2014)
3. M. Beylot, Regulation of in vivo ketogenesis: role of free fatty acids and control by epinephrine, thyroid hormones, insulin and glucagon. Diabetes Metab. 22, 299–304 (1996)
4. J.A. Edge, D.A. Harris, P.E. Phillips, B.R. Pal, D.R. Matthews, D.B. Dunger, Evidence for a role for insulin and growth hormone in overnight regulation of 3-hydroxybutyrate in normal and diabetic adolescents. Diabetes Care 16, 1011–1018 (1993)
5. M. Beylot, S. Picard, C. Chambrier, H. Vidal, M. Laville, R. Cohen, A. Cotisson, R. Mornex, Effect of physiological concentrations of insulin and glucagon on the relationship between nonesterified fatty acids availability and ketone body production in humans. Metabolism 40, 1138–1146 (1991)
6. G.E. Umpierrez, D. Smiley, A.E. Kitabchi, Narrative review: ketosis-prone type 2 diabetes mellitus. Ann. Intern. Med. 144, 350–357 (2006)
7. B. Zinman, C. Wanner, J.M. Lachin, D. Fitchett, E. Bluhmki, S. Hantel, M. Mattheus, T. Devins, O.E. Johansen, H.J. Woerle, U.C. Broedl, S.E. Inzucchi, EMPA-REG OUTCOME Investigators Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N. Engl. J. Med. 373, 2117–2128 (2015)
8. E. Ferrannini, S. Baldi, S. Frascerra, B. Astiarraga, T. Heise, R. Bizzotto, A. Mari, T.R. Pieber, E. Muscelli, Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes. Diabetes 65, 1190–1195 (2016)
9. Y. Kao, C.-C. Hsu, S.-F. Weng, H.-J. Lin, J.-J. Wang, S.-B. Su, C.-C. Huang, H.-R. Guo, Subsequent mortality after hyperglycemic crisis episode in the non-elderly: a national population-based cohort study. Endocrine 51, 72–82 (2016)
10. C.L. Morgan, J. Mukherjee, S. Jenkins-Jones, S.E. Holden, C.J. Currie, Combination therapy with metformin plus sulphonylureas versus metformin plus DPP-4 inhibitors: association with major adverse cardiovascular events and all-cause mortality. Diabetes. Obes. Metab. 16, 977–983 (2014)
11. U. Anyanwagu, J. Mamza, R. Mehta, R. Donnelly, I. Idris Cardiovascular events and all-cause mortality with insulin versus glucagon-like peptide-1 analogue in type 2 diabetes. Heart. (2016).
12. C.A. Bannister, S.E. Holden, S. Jenkins-Jones, C.L. Morgan, J.P. Halcox, G. Schernthaner, J. Mukherjee, C.J. Currie, Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls. Diabetes. Obes. Metab. 16, 1165–1173 (2014)
13. W.W. Winder, D.G. Hardie, AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am. J. Physiol 277, E1–E10 (1999)
14. C. Wolfrum, E. Asilmaz, E. Luca, J.M. Friedman, M. Stoffel, Foxa2 regulates lipid metabolism and ketogenesis in the liver during fasting and in diabetes. Nature 432, 1027–1032 (2004)
15. G. Aubert, O.J. Martin, J.L. Horton, L. Lai, R.B. Vega, T.C. Leone, T. Koves, S.J. Gardell, M. Krüger, C.L. Hoppel, E.D. Lewandowski, P.A. Crawford, D.M. Muoio, D.P. Kelly, The Failing Heart Relies on Ketone Bodies as a Fuel. Circulation 133, 698–705 (2016)
16. Y.-C. Tsai, Y.-C. Chou, A.-B. Wu, C.-M. Hu, C.-Y. Chen, F.-A. Chen, J.-A. Lee, Stereoselective effects of 3-hydroxybutyrate on glucose utilization of rat cardiomyocytes. Life Sci 78, 1385–1391 (2006)
17. P. Fioretto, R. Trevisan, M. Velussi, A. Cernigoi, C. De Riva, M. Bressan, A. Doria, N. Pauletto, P. Angeli, C. De Donà, Glomerular filtration rate is increased in man by the infusion of both D,L-3-hydroxybutyric acid and sodium D,L-3-hydroxybutyrate. J. Clin. Endocrinol. Metab. 65, 331–338 (1987)
18. T. Wei, W. Tian, F. Liu, G. Xie, Protective effects of exogenous β-hydroxybutyrate on paraquat toxicity in rat kidney. Biochem. Biophys. Res. Commun. 447, 666–671 (2014)
19. R. Trevisan, R. Nosadini, P. Fioretto, A. Avogaro, E. Duner, E. Jori, A. Valerio, A. Doria, G. Crepaldi, Ketone bodies increase glomerular filtration rate in normal man and in patients with type 1 (insulin-dependent) diabetes mellitus. Diabetologia 30, 214–221 (1987)
20. S.I. Taylor, J.E. Blau, K.I. Rother, SGLT2 Inhibitors May Predispose to Ketoacidosis. J. Clin. Endocrinol. Metab. 100, 2849–2852 (2015)
21. C. Wanner, S.E. Inzucchi, J.M. Lachin, D. Fitchett, M. von Eynatten, M. Mattheus, O.E. Johansen, H.J. Woerle, U.C. Broedl, B. Zinman, EMPA-REG OUTCOME Investigators empagliflozin and progression of kidney disease in type 2 diabetes. N. Engl. J. Med. (2016)